Polypharmacy Increases to 35.7% Among Older Adults, Leaving 22.3% at Risk for Major Drug Interactions

The National Social Life, Health and Aging Project data showed concurrent prescription and supplement use climbing, with dietary supplement polypharmacy reaching 16.7%. Antidepressants, statins, and antiplatelet agents drove most high-risk combinations, echoing patterns in prior observational cohorts where serotonergic and antithrombotic overlaps predominate. This persistence signals that simple counts of medications miss the therapeutic class clustering that amplifies bleeding, arrhythmia, and serotonin syndrome risks in real-world geriatric care.

Broader context reveals gaps beyond the JAMA snapshot. A 2023 Lancet Healthy Longevity analysis of Medicare data linked similar polypharmacy trajectories to 1.5-fold higher hospitalization rates for adverse events, yet routine Beers Criteria screening remains underused in primary care. The slight drop in interaction prevalence may reflect statin dose adjustments or SSRI alternatives, but rising supplement use introduces unmonitored CYP interactions that electronic health records rarely capture.

Next steps require targeted deprescribing trials focused on antidepressant-statin regimens rather than blanket polypharmacy reduction. Implementation studies should test pharmacist-led reviews integrated with Medicare Part D data to measure reductions in actual clinical events, not just prescription counts, over three-year follow-up.